Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 3Vomiting 1Endometrial Neoplasms 1Cachexia 1Anorexia 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × Megestrol × Clear all
NCT00420563 2026-03-16

PAL-ANGI

Centre Oscar Lambret

Phase 2 Completed
88 enrolled
Tumor-Agnostic

Neoplasms

NCT03283488 2023-07-07

Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.

University of Sao Paulo

Phase 2 Completed
52 enrolled

Anorexia, Cachexia, Neoplasms

NCT04430361 2020-06-12

the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Henan Cancer Hospital

Phase 2 Unknown
120 enrolled

Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡